Press release content from PR Newswire. The AP news staff was not involved in its creation.
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
May 6, 2021 GMT
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, May 6, 2021 /PRNewswire/ With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic international agreements with four companies – DexCom, Inc., Glooko Inc., myDiabby Healthcare and Roche – to advance connected solutions and streamline care for people living with diabetes in markets outside of the United States. These companies offer unique diabetes management platforms that will be compatible with Lilly’s Tempo Pen™ (approved in several global markets) and Tempo Smart Button™ (currently in late-stage development) to support peo
Roche collaborates with Lilly to support people with diabetes on insulin pen therapy
- Roche and Lilly will integrate data from Lilly s connected insulin pen solution into the mySugr app in several countries.
- Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals.
- By collaborating with Lilly, Roche accelerates growth of its open ecosystem enabling its strategy of integrated Personalised Diabetes Management (iPDM).
BASEL, Switzerland, May 6, 2021 /PRNewswire/ Roche today announced that it has signed a collaboration agreement with Eli Lilly and Company, a global leader in diabetes care delivering innovative solutions including medicines and technologies, to work towards optimising the management of insulin pen therapy. By collaborating with Lilly, Roche follows its ambition to create an open ecosystem including its own and partner devices, sol
06 maggio 2021 12:51
Fonte: Adnkronos
#salute-e-benessere
- Roche and Lilly will integrate data from Lilly s connected insulin pen solution into the mySugr app in several countries.
- Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals.
- By collaborating with Lilly, Roche accelerates growth of its open ecosystem enabling its strategy of integrated Personalised Diabetes Management (iPDM).
BASEL, Switzerland, May 6, 2021 /PRNewswire/ Roche today announced that it has signed a collaboration agreement with Eli Lilly and Company, a global leader in diabetes care delivering innovative solutions including medicines and technologies, to work towards optimising the management of insulin pen therapy. By collaborating with Lilly, Roche follows its ambition to create an open ecosystem including its own and partner devices, solutions and services, a
Roche Diabetes Care announces launch of new Accu-Chek® Instant system to support iPDM pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } }); The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche s strategy of integrated Personalised Diabetes Management (iPDM).
BASEL, Dec. 11, 2020 /PRNewswire/ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it is partnering with the French MedTech company Diabeloop to advance the management of insulin pump therapy, creating new opportunities to lower the burden of constant insulin dose adjustment for people with diabetes and to improve therapy outcomes(1). The partnership marks Roche s first step in the field o